The Surgical Management of Cervical Cancer

Roque, Dario R.; Wysham, Weiya Z.; Soper, John T.

doi:10.1097/ogx.0000000000000089

Cited by 25 publications

(18 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, SLN evaluation is now standard of care in breast cancer and melanoma [14,15], as well as in vulvar cancer [16]. Evaluation of SLNs in select cervical cancer cases is now performed in gynecologic oncology practices worldwide and may soon emerge as a part of routine care [17][18][19], however its acceptance in endometrial cancer is more controversial.…”

Section: Introductionmentioning

confidence: 99%

Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research

Cormier

Rozenholc

Gotlieb

et al. 2015

Gynecologic Oncology

135

133

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research

Cormier

Rozenholc

Gotlieb

et al. 2015

Gynecologic Oncology

135

133

View full text Add to dashboard Cite

“…The clear to lightly eosinophilic cytoplasm shown by these tumours may also lead to confusion with clear cell carcinoma . Given the therapeutic and prognostic differences, accurate distinction of gastric‐type EA from endometrial carcinoma is critical …”

Section: Introductionmentioning

confidence: 99%

“…10,22 Given the therapeutic and prognostic differences, accurate distinction of gastric-type EA from endometrial carcinoma is critical. [23][24][25] With this information in mind, we sought to assess the immunohistochemical expression patterns of MUC6 and HIK1083 in a cohort of endometrial carcinomas, with the aim of elucidating the utility of these markers in differentiating gastric-type EA from some of its mimics arising from the uterine corpus.…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical expression of HIK1083 and MUC6 in endometrial carcinomas

2019

View full text Add to dashboard Cite

Aims Gastric‐type endocervical adenocarcinoma (EA) is characterised by aggressive behaviour and pathogenesis independent of human papillomavirus infection. Because of its morphology and frequent mutation‐pattern expression of p53, gastric‐type EA may be confused with several types of endometrial carcinoma, particularly in biopsy and curettage specimens. HIK1083 and MUC6 are immunohistochemical markers used to support a diagnosis of gastric‐type EA; however, the rates of expression of these markers in endometrial tumours are largely unknown. We therefore aimed to assess the expression of HIK1083 and MUC6 in a cohort of different types of endometrial carcinoma. Methods and results Ninety‐one endometrial carcinomas (56 endometrioid, 16 clear cell, and 19 serous) from 91 patients treated with hysterectomy were included. A representative tumour block from each case was used for immunohistochemical staining with HIK1083 and MUC6. The percentage of stained cells (0–100%) and average staining intensity (weak, moderate, and strong) were recorded for both markers. None of 91 cases expressed HIK1083. In contrast, 66% (60/91) of cases showed at least focal expression of MUC6; importantly, 54 of 60 (90%) positive cases showed moderate or strong staining. Five of 60 (8%) cases showed MUC6 staining in ≥50% of tumour cells. Endometrioid tumours (49/56, 88%) were more likely to express MUC6 than cases of clear cell (1/16, 6%) or serous (10/19, 53%) carcinoma. Discussion Endometrial carcinoma often expresses MUC6. In contrast, HIK1083 is consistently negative, and thus, when positive, is a more reliable marker for distinguishing gastric‐type EA from some of its endometrial mimics.

show abstract

“…Despite advances in the diagnosis, treatment and prevention of the disease, the prognosis of patients remains poor. The median progression-free survival and overall survival range between 2.5 and 13.2 months, and 4.2 and 12.87 months, respectively (7,8). Therefore, a complete understanding of the mechanisms underlying the occurrence and development of cervical cancer are required for the development of novel, effective therapeutic strategies.…”

Section: Introductionmentioning

confidence: 99%

microRNA‑211 suppresses the growth and metastasis of cervical cancer by directly targeting ZEB1

Huang

Xie

et al. 2017

Mol Med Report

View full text Add to dashboard Cite

Of gynecological cancers, cervical cancer has the second highest incidence globally and is a major cause of cancer‑associated mortality in women. An increasing number of studies have reported that microRNAs (miRNAs) have important roles in cervical cancer carcinogenesis and progression through regulation of various critical protein‑coding genes. The aim of the present study was to investigate the expression and biological roles of miRNA‑211 (miR‑211) in cervical cancer and its underlying molecular mechanism. The results of reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) demonstrated that the expression levels of miR‑211 in cervical cancer tissues and cell lines were significantly lower compared with adjacent normal tissues and the normal human cervix epithelial cell line, respectively. Furthermore, upregulation of miR‑211 by transfection with miR‑211 mimics inhibited cell proliferation, migration and invasion of cervical cancer, as determined by MTT, Transwell and Matrigel assays, respectively. Bioinformatics analysis and luciferase reporter assay results indicated that zinc finger E‑box binding homeobox 1 (ZEB1) may be a direct target gene of miR‑211. In addition, RT‑qPCR and western blot analysis results demonstrated that miR‑211 overexpression markedly reduced ZEB1 expression at mRNA and protein levels in cervical cancer. Furthermore, the effects of ZEB1 downregulation on the proliferation, migration and invasion of cervical cancer cells were similar to those induced by miR‑211 overexpression. These results indicate that miR‑211 may act as a tumor suppressor in cervical cancer by directly targeting ZEB1. Therefore, miR‑211/ZEB1‑based targeted therapy may represent a potential novel treatment for patients with cervical cancer.

show abstract

The Surgical Management of Cervical Cancer

Cited by 25 publications

References 120 publications

Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research

Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research

Immunohistochemical expression of HIK1083 and MUC6 in endometrial carcinomas

microRNA‑211 suppresses the growth and metastasis of cervical cancer by directly targeting ZEB1

Contact Info

Product

Resources

About